RNAZ Transcode Therapeutics
- 1.160
- +0.345+42.38%
- 1.150
- -0.010-0.87%
Transcode Therapeutics News
Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Zdravka Medarova(0.4%)
Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Tang Capital Partners, LP(0.0%),Tang Capital Management, LLC(0.0%), etc.
Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(0.1%),Lind Global Partners II LLC(0.1%), etc.
Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.
Transcode Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Robert Michael Dudley(1.9%)
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Fitzgerald Thomas A
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Dudley Robert Michael
Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Tang Capital Partners, LP(9.99%),Tang Capital Management, LLC(9.99%), etc.
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Dudley Robert Michael
Transcode Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Robert Michael Dudley(6.0%)
Transcode Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Chief Executive Officer Dudley Robert Michael
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Dudley Robert Michael
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Marquet Magda
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Fitzgerald Thomas A
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Dudley Robert Michael
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manting Erik
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Marquet Magda
Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe
Analysis
Price Target
No Data
